Cidara Therapeutics, the biotech firm developing drug-Fc conjugate (DFC) therapeutics via its proprietary Cloudbreak platform, has announced it has achieved full enrollment in its Phase 3 ANCHOR trial, reaching 6,000 participants across sites in the US and UK. 

The trial is testing CD388, a non-vaccine preventative for seasonal influenza, in high-risk populations—including individuals over 65, those with certain comorbidities, and immune-compromised patients. 

“Achieving our target enrollment of 6,000 participants ahead of the peak of flu season in the Northern Hemisphere is an important step in our efforts to evaluate CD388 as a potential single-dose, non-vaccine influenza preventative for those at high risk of complications from influenza,” said Jeffrey Stein, Ph.D., President and CEO of Cidara. 

ANCHOR is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial. 

CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents.  

The trial includes an interim analysis in Q1 2026 to assess trial assumptions and determine if additional enrollment is needed during the Southern Hemisphere flu season. If successful, results from this trial alone could support potential BLA approval for the high-risk populations represented.